FDA Approves Eli Lilly's Trulicity to Reduce Cardiovascular Events in Type 2 Diabetes Patients
The approval should help the big pharmaceutical fight off competition from other drugs in the same class.
Eli Lilly and Company
LLY
LLY
$135.41
-$2.74
-2.0%
Price as of February 25, 2020, 4:15 p.m. EST
View Interactive LLY Charts
The Company discovers, develops, manufactures and sells products in one of its business segment of pharmaceutical products to prevent and treat human diseases.
Interactive Chart
News & Analysis: Eli Lilly and Company
The Fool has written over 900 articles on Eli Lilly and Company.
Better Buy: GlaxoSmithKline vs. Eli Lilly
These two big drugmakers are in very different positions right now. And one is the clear choice for long-term investors.
Oscar Health Cuts Co-Pays on About 100 Drugs to $3
The health insurer hopes that making prescriptions affordable will keep the people it covers healthier, which should save it money in the long run.
Better Buy: AbbVie vs. Eli Lilly
Which of these top dividend growth stocks is the more attractive buy right now?
Eli Lilly and Incyte Record Another Positive Clinical Trial for Olumiant Works in Eczema
The drug moves closer to an expanded approval for the skin disorder.
A Double Failure of Alzheimer's Drugs
Lilly and Roche reported their latest disappointments in attempting to effectively treat Alzheimer's by attacking amyloid plaques.
Stock Market News: Coronavirus Hits NIO; Lilly Suffers Alzheimer's Defeat
The market moved higher to start the week.
4 Dates Biotech Investors Should Circle in February
From a niche contraceptive to the world's top cancer treatment, the FDA has a number of interesting drugs it's reviewing this month.
Eli Lilly Launches a New Migraine Drug
Reyvow is the first drug in an entirely new class of acute migraine treatments.
Eli Lilly & Co (LLY) Q4 2019 Earnings Call Transcript
LLY earnings call for the period ending December 31, 2019.
